- Home
- ROIV vs PHM Comparison
ROIV vs PHM Comparison
Compare ROIV & PHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | PHM |
|---|---|---|
| Founded | 2014 | 1950 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 22.5B |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ROIV | PHM |
|---|---|---|
| Price | $27.67 | $120.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 13 |
| Target Price | $28.94 | ★ $136.23 |
| AVG Volume (30 Days) | ★ 4.5M | 1.8M |
| Earning Date | 05-28-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.83% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.79 |
| Revenue | ★ $29,053,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $744.61 | $4.50 |
| P/E Ratio | ★ N/A | $69.63 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.58 | $95.20 |
| 52 Week High | $30.33 | $144.50 |
Technical Indicators
Market Signals| Indicator | ROIV | PHM |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 44.52 |
| Support Level | $26.94 | $113.93 |
| Resistance Level | $27.94 | $122.27 |
| Average True Range (ATR) | 0.87 | 3.71 |
| MACD | -0.20 | 0.23 |
| Stochastic Oscillator | 17.95 | 12.56 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About PHM PulteGroup Inc.
PulteGroup Inc is a homebuilder in the United States. The company mainly builds single-family detached homes and offers products to entry-level, move-up, and active-adult buyers. It also offers homebuyers mortgage financing, title, and insurance agency services through its financial services segment.